D. Milojkovic

K. Rezvani, D. Marin, J. Goldman, 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Introducing a Predictive Score for Successful Treatment Free Remission in Chronic Myeloid Leukemia (CML).

J. Byrne, M. Copland, R. Clark, 2019, Blood.

De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial.

J. Byrne, M. Copland, R. Clark, 2019, The Lancet. Haematology.

Efficacy and Safety of Ponatinib in Chronic Phase-Chronic Myeloid Leukemia (CP-CML) According to the Extent of Treatment with Prior Tyrosine Kinase Inhibitors (TKIs): Final (5-Year) Results of the PACE Study

H. Kantarjian, J. Cortes, M. Deininger, 2017 .

Can the Combination of the Measurement of BCR-ABL1 Transcript Levels At 3 and 6 Months Improve the Prognostic Value of the 3 Month Measurement?

D. Marin, J. Goldman, L. Foroni, 2012 .

Interferon-alpha or homoharringtonine as salvage treatment for chronic myeloid leukemia patients who acquire the T315I BCR-ABL mutation.

D. Marin, J. Goldman, D. Milojković, 2007, Blood.

How I treat leukemia during pregnancy.

J. Apperley, D. Milojković, D. Milojkovic, 2014, Blood.

2 prior lines of TKI therapy failed patients with chronic myeloid leukemia in chronic phase who have Efficacy of tyrosine kinase inhibitors (TKIs) as third-line therapy in

K. Rezvani, J. Goldman, L. Foroni, 2013 .

MR4 sustained for 12 months is associated with stable deep molecular responses in chronic myeloid leukemia

L. Foroni, D. Milojković, J. Apperley, 2019, Haematologica.

Brief report EVI-1 oncogene expression predicts survival in chronic-phase CML patients resistant to imatinib treated with second-generation tyrosine kinase inhibitors

D. Marin, J. Goldman, L. Foroni, 2010 .

The Use of Dasatinib in Chronic Myeloid Leukemia: Some Practical Considerations

D. Marin, J. Goldman, M. Bua, 2007 .

Deletions adjacent to BCR and ABL1 breakpoints occur in a substantial minority of chronic myeloid leukemia patients with masked Philadelphia rearrangements.

D. Marin, A. Reid, J. Apperley, 2008, Cancer genetics and cytogenetics.

Fecal Microbiota Transplant Mitigates Adverse Outcomes Seen in Patients Colonized With Multidrug-Resistant Organisms Undergoing Allogeneic Hematopoietic Cell Transplantation

J. Marchesi, F. Davies, E. Brannigan, 2021, Frontiers in Cellular and Infection Microbiology.

Donor Lymphocyte Infusions for Chronic Myeloid Leukemia Relapsing after Allogeneic Stem Cell Transplantation: May We Predict Graft-versus-Leukemia Without Graft-versus-Host Disease?

N. Kröger, S. Iacobelli, A. Gratwohl, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Patient-reported outcomes in the phase 3 BFORE trial of bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia

T. Brümmendorf, J. Cortes, M. Deininger, 2019, Journal of Cancer Research and Clinical Oncology.

Impact of route and adequacy of nutritional intake on outcomes of allogeneic haematopoietic cell transplantation for haematologic malignancies.

M. Hickson, D. Milojković, A. Chaidos, 2019, Clinical nutrition.

Predicting ultrahigh risk multiple myeloma by molecular profiling: an analysis of newly diagnosed transplant eligible myeloma XI trial patients

G. Morgan, A. Mead, R. Houlston, 2020, Leukemia.

KIR2DS1 genotype predicts for complete cytogenetic response and survival in newly diagnosed chronic myeloid leukemia patients treated with imatinib

D. Marin, L. Foroni, D. Milojković, 2012, Leukemia.

COVID-19 vaccine boosted immunity against Omicron in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors

D. Altmann, R. Boyton, C. Pade, 2022, Leukemia.

Multi-arm Trial of Inflammatory Signal Inhibitors (MATIS) for hospitalised patients with mild or moderate COVID-19 pneumonia: a structured summary of a study protocol for a randomised controlled trial

J. Wason, A. Katsarou, G. Cooke, 2021, Trials.

Tyrosine kinase inhibitors impair B-cell immune responses in CML through off-target inhibition of kinases important for cell signaling.

K. Rezvani, D. Marin, E. Shpall, 2013, Blood.

through off-target inhibition of kinases important for cell signaling Tyrosine kinase inhibitors impair B-cell immune responses in CML

D. Marin, E. Shpall, D. Milojković, 2013 .

C‐reactive protein prior to myeloablative allogeneic haematopoietic cell transplantation identifies patients at risk of early‐ and long‐term mortality

A. Chaidos, H. Auner, A. Karadimitris, 2018, British journal of haematology.

Repeated vaccination is required to optimize seroprotection against H1N1 in the immunocompromised host

K. Rezvani, D. Marin, J. Goldman, 2011, Haematologica.

Microenvironment Produced by Acute Myeloid Leukemia Cells Prevents T Cell Activation and Proliferation by Inhibition of NF-κB, c-Myc, and pRb Pathways

G. Mufti, M. Arno, N. Lea, 2001, The Journal of Immunology.

Third primary SARS-CoV-2 mRNA vaccines enhance antibody responses in most patients with haematological malignancies

D. Milojković, A. Chaidos, M. Bua, 2022, Nature Communications.

Results of a national UK physician reported survey of COVID-19 infection in patients with a myeloproliferative neoplasm

A. Mead, A. Godfrey, M. McMullin, 2021, Leukemia.

Interleukin 6‐blockade treatment for severe COVID‐19 in two patients with multiple myeloma

A. Katsarou, A. Chaidos, A. Karadimitris, 2020, British journal of haematology.

Carfilzomib Enhances the Suppressive Effect of Ruxolitinib in Myelofibrosis

K. Naresh, M. Deininger, K. Ponnusamy, 2021, Cancers.

MSQoL-54 predicts change in fatigue after inpatient rehabilitation for people with multiple sclerosis

T. Pekmezović, T. Gazibara, J. Drulovic, 2013, Disability and rehabilitation.

Cardiovascular risk in chronic myeloid leukaemia: A multidisciplinary consensus on screening and management

C. Manisty, S. Purcell, K. Amer, 2023, European journal of haematology.

Long-term persistence of natural anti-SARS-CoV-2 antibodies and mild impact of SARS-CoV-2 infection in CML patients: results from a seroprevalence study

R. Tedder, J. Apperley, Myra O. McClure, 2022, Leukemia & lymphoma.

Lymphoid blast crisis after prolonged treatment‐free remission in chronic myeloid leukaemia after tyrosine kinase inhibitor de‐escalation during the COVID‐19 pandemic

C. Pocock, D. Yallop, V. Potter, 2021, EJHaem.

TKI dose reduction can effectively maintain major molecular remission in patients with chronic myeloid leukaemia

L. Foroni, D. Milojković, J. Apperley, 2020, British journal of haematology.

Real‐world tyrosine kinase inhibitor treatment pathways, monitoring patterns and responses in patients with chronic myeloid leukaemia in the United Kingdom: the UK TARGET CML study

A. Mead, J. Byrne, R. Clark, 2020, British journal of haematology.

Initial reduction of therapy prior to complete treatment discontinuation in chronic myeloid leukaemia: final results of the British DESTINY Study

J. Byrne, M. Copland, R. Clark, 2019 .

Efficacy of combining dasatinib and FLAG-IDA for patients with chronic myeloid leukemia in blastic transformation

D. Marin, L. Foroni, A. Reid, 2012, Haematologica.

Graft invariant natural killer T-cell dose predicts risk of acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation.

D. Marin, J. Goldman, I. Roberts, 2012, Blood.

Interaction between KIR3DS1 and HLA-Bw4 predicts for progression-free survival after autologous stem cell transplantation in patients with multiple myeloma.

K. Rezvani, D. Marin, L. Foroni, 2010, Blood.

Humoral and cellular immunity to primary H1N1 infection in patients with hematologic malignancies following stem cell transplantation.

S. Brett, K. Rezvani, D. Marin, 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Salvage autologous stem cell transplantation for multiple myeloma relapsing or progressing after up-front autologous transplantation

D. Marin, A. Chaidos, H. Auner, 2013, Leukemia & lymphoma.

Analysis of hematopoietic recovery after autologous transplantation as method of quality control for long-term progenitor cell cryopreservation

A. Chaidos, H. Auner, O. Pello, 2017, Bone Marrow Transplantation.

Single-cell analyses reveal aberrant pathways for megakaryocyte-biased hematopoiesis in myelofibrosis and identify mutant clone-specific targets

Elisabeth F. Heuston, Supat Thongjuea, A. Mead, 2019, bioRxiv.

Hypereosinophilic syndrome: an indolent rash with a serious cardiac complication

D. Milojković, D. Lefroy, S. Wakelin, 2016, Clinical and experimental dermatology.

Escalating-dose HLA-mismatched DLI is safe for the treatment of leukaemia relapse following alemtuzumab-based myeloablative allo-SCT

D. Slade, D. Marin, J. Goldman, 2013, Bone Marrow Transplantation.

Complete remission with incomplete count recovery (CRi) prior to allogeneic HCT for acute myeloid leukaemia is associated with a high non-relapse mortality

D. Milojković, P. May, D. Bansal, 2019, Leukemia.

The outcome of post-transplant asciminib in patients with chronic myeloid leukaemia

J. Byrne, M. Copland, J. Apperley, 2023, Bone Marrow Transplantation.

The Majority of Patients Receiving Donor Lymphocyte Infusions for Relapsed Chronic Myeloid Leukemia Remain PCR Positive Despite Maintaining Long-Term Remission,

K. Rezvani, D. Marin, J. Goldman, 2011 .

Response To Ruxolitinib In Patients With Intermediate-1, Intermediate-2 and High-Risk Myelofibrosis: Interim Results Of The UK Robust Trial

A. Mead, R. Clark, J. Chacko, 2013 .

Matched Pair Analysis of Intravenous vs Oral Busulphan as Part of Fludarabine-Busulphan-Campath (Alemtuzumab) Reduced Intensity Conditioning (RIC) Haematopoietic Stem Cell Transplantation (HSCT).

G. Mufti, Z. Lim, L. Pearce, 2005 .

European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia.

M. Baccarani, G. Rosti, K. Porkka, 2016, Leukemia.

Abnormally Small BCR-ABL Transcripts in CML Patients before and during Imatinib Treatment.

J. Melo, D. Marin, S. Kamel‐Reid, 2006 .

A new rapid and sensitive assay for detecting the T315I BCR-ABL kinase domain mutation in chronic myeloid leukaemia

J. Goldman, L. Foroni, N. Thelwell, 2008, Journal of Clinical Pathology.

Next-Generation Sequencing-Assisted DNA-Based Digital PCR for a Personalized Approach to the Detection and Quantification of Residual Disease in Chronic Myeloid Leukemia Patients.

D. Kasperavičiūtė, J. Huggett, Michael Mueller, 2016, The Journal of molecular diagnostics : JMD.

for chronic myeloid leukemia patients on long-term therapy Poor adherence is the main reason for loss of CCyR and imatinib failure

K. Rezvani, D. Marin, L. Foroni, 2013 .

Brief report Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy

K. Rezvani, D. Marin, J. Goldman, 2011 .

Significant weight gain in patients with chronic myeloid leukemia after imatinib therapy.

D. Marin, J. Goldman, L. Foroni, 2012, Blood.

Antiapoptotic Microenvironment of Acute Myeloid Leukemia

G. Mufti, D. Milojković, N. Westwood, 2004, The Journal of Immunology.

Myeloid Leukemia Antiapoptotic Microenvironment of Acute

G. Mufti, D. Milojković, N. S. Thomas, 2004 .

Imatinib and chronic myeloid leukemia: close to the bone

E. Terpos, D. Milojković, J. Apperley, 2013, Leukemia & lymphoma.

Phazar: A Phase Ib Study to Assess the Safety and Tolerability of Ruxolitinib in Combination with Azacitidine in Advanced Phase Myeloproliferative Neoplasms (MPN), Including Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukaemia (AML) Arising from MPN [ISRCTN16783472]

A. Mead, C. Yap, J. Byrne, 2020 .

Spliceosome mutations are common in persons with myeloproliferative neoplasm-associated myelofibrosis with RBC-transfusion-dependence and correlate with response to pomalidomide

M. Cazzola, H. Deeg, R. Schlenk, 2020, Leukemia.

E14a2 BCR-ABL1 transcript is associated with a higher rate of treatment-free remission in individuals with chronic myeloid leukemia after stopping tyrosine kinase inhibitor therapy

R. Clark, R. Gale, L. Foroni, 2017, Haematologica.

Clinical and Immunological Studies in Chronic Myeloid Leukaemia

S. Söderlund, D. Milojkovic, Stina Söderlund, 2017 .

The Natural History of RTQ-PCR Levels After the Achievement of Complete Molecular Remission (CMR): Implications for ‘Stopping' Studies

D. Marin, J. Goldman, L. Foroni, 2011 .

Responses to second-line tyrosine kinase inhibitors are durable : an intention-to-treat analysis in chronic myeloid leukemia patients

K. Rezvani, D. Marin, J. Goldman, 2012 .

Responses to second-line tyrosine kinase inhibitors are durable: an intention-to-treat analysis in chronic myeloid leukemia patients.

K. Rezvani, D. Marin, J. Goldman, 2012, Blood.

Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: 12-Month Patient-Reported Outcomes from the BFORE Trial

T. Brümmendorf, J. Cortes, M. Deininger, 2017 .

Clonal gammopathies following alemtuzumab-based reduced intensity conditioning haematopoietic stem cell transplantation: association with chronic graft-versus-host disease and improved overall survival

G. Mufti, R. Brand, Z. Lim, 2007, Bone Marrow Transplantation.

Dose-limiting dermatological toxicity secondary to imatinib mesylate (STI571) in chronic myeloid leukaemia

J. Salisbury, G. Mufti, D. Creamer, 2003, Leukemia.

The level of BCR-ABL1 kinase activity before treatment does not identify chronic myeloid leukemia patients who fail to achieve a complete cytogenetic response on imatinib

J. Melo, D. Marin, J. Goldman, 2009, Haematologica.

The UK SPIRIT 1 trial in newly-diagnosed chronic myeloid leukaemia (CML)

J. Byrne, R. Clark, J. Goldman, 2022, British journal of haematology.

Excellent outcome after repeated changes of tyrosine kinase inhibitor therapy for chronic myeloid leukaemia in complete cytogenetic response due to minor side effects

K. Rezvani, D. Marin, J. Goldman, 2014, British journal of haematology.

The influence of salivary amylase on total amylase elevation in CML patients treated with TKI therapy: a case series of 3 patients

D. Milojković, J. Apperley, J. Khorashad, 2019, Leukemia & lymphoma.

Escalating-Dose HLA-mismatched donor lymphocyte infusion is safe for the treatment of 1 leukaemia relapse following alemtuzumab-based myeloablative allogeneic stem cell 2 transplantation.

D. Slade, K. Rezvani, J. Goldman, 2013 .

How I treat leukemia during pregnancy.

J. Apperley, D. Milojkovic, 2014, Blood.

EVI-1 oncogene expression predicts survival in chronic-phase CML patients resistant to imatinib treated with second-generation tyrosine kinase inhibitors.

R. Clark, D. Marin, J. Goldman, 2010, Blood.

The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts.

J. Radich, H. Kantarjian, D. B. Yehuda, 2013, Blood.

Patient-reported outcomes in the phase 3 BFORE trial of bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia

T. Brümmendorf, J. Cortes, M. Deininger, 2019, Journal of Cancer Research and Clinical Oncology.

Platelet dysfunction associated with ponatinib, a new pan BCR-ABL inhibitor with efficacy for chronic myeloid leukemia resistant to multiple tyrosine kinase inhibitor therapy

D. Marin, J. Goldman, M. Laffan, 2012, Haematologica.

The role of ibrutinib in COVID-19 hyperinflammation: A case report

A. Chaidos, S. Maynard, H. Sharp, 2021, International Journal of Infectious Diseases.

Assessment of BCR-ABL1 Transcript Levels At 3 Months Is the Only Requirement for Predicting Outcome for Patients with Chronic Myeloid Leukemia Treated with Imatinib

R. Clark, D. Marin, J. Goldman, 2011 .

A Single-Cell Approach to Unraveling Abnormal Megakaryocyte Differentiation and Function in Myelofibrosis

Elisabeth F. Heuston, Nikolaos Barkas, A. Mead, 2017 .

Ruxolitinib for tocilizumab‐refractory severe COVID‐19 infection

D. Milojković, J. Apperley, L. Cook, 2020, British journal of haematology.